Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … Farxiga was the company's second‑highest‑selling product in 2020 (after Lisinopril). The 2020 sales reflect a mix of continued growth in type‑2‑diabetes prescriptions and a rapid expansion into heart‑failure indications in several markets. Financial summary – Total Revenue, comprising Product Sales and Collaboration Revenue, increased by 9% in the year (10% at CER) to $26,617m. Product Sales grew by 10% (11% at CER) to $25,890m, driven primarily by the performances of the new medicines across Oncology and BioPharmaceuticals, including Tagrissoand Farxiga. Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … A geographical split of Product Sales is shown in Note 7. For additional details, refer to Table 49: Historic Collaboration Revenue for Collaboration Revenue recognised during FY 2020 and FY 2019. Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. Annual Sales of Farxiga reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive … In the U.S. Farxiga sales grew by 6% to $569 million (2019: $537 million; 2018: $591 million), partly driven by a regulatory approval in May 2020 for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) in both patients with and without T2D, based on the ground-breaking DAPA-HF trial. According to the forecasts, Trulicity, an injectable diabetes medication manufactured by pharmaceutical company Eli Lilly, will have the highest sales in both 2020 and 2024 as they are estimated … Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. Annual Sales of Dapagliflozin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. It also provides analysis of Dapagliflozin sales forecasts, along with factors driving its market. Dapagliflozin Drug Summary Dapagliflozin, marketed as Farxiga, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. Farxiga 2020 U.S. PROMOTIONAL AUDIT REPORT Published July 2021 • 24 Pages The 5 Key Questions Addressed by this Report: How many physicians were reached by Farxiga through reportable promotional activity in 2020 and how does this compare to its peer set in the Heart Failure, Reduce Risk of Major Cardiovascular Events, and Type 2 Diabetes – SGLT2 markets? What promotional mix was leveraged … Invokana (canagliflozin, Janssen) Steglatro (ertugliflozin, Merck) FARXIGA's differentiation stems from its approval in multiple indications, notably HFrEF and CKD, beyond T2DM. Revenue Performance and Sales Trends AstraZeneca reported global sales of USD 4.3 billion for FARXIGA in 2022, a 25% increase from 2021 [4]. Product Sales grew by 15% (11% at CER) to $7,257m, driven primarily by the performances of new medicines across Oncology and BioPharmaceuticals, including Tagrisso and Farxiga. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. CEO Pascal Soriot remarked that "2022 has started strongly for AstraZeneca," adding "Farxiga achieved $1 billion revenue in the quarter and our oncology medicines delivered product sales growth of 18% [on a constant exchange rate basis], despite COVID-19 continuing to impact cancer diagnosis and … The Global Dapagliflozin Market was valued at USD 3.21 Billion in 2024 and is expected to reach USD 5.47 Billion by 2032, growing at a CAGR of 6.70% (2025-2032). Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Explore the FARXIGA Market trends, size, and future outlook with DelveInsight's latest report. Gain insights into Companies, emerging therapies, and forecasts In the decade since AstraZeneca's Farxiga first nabbed FDA approval to treat adults with type 2 diabetes, the drug has well surpassed blockbuster status, racking up additional indications and generating nearly $6 billion in sales in 2023. And it hasn't reached its peak yet, according to a … Total Revenue increased by 13% (9% at CER) in the year, driven by strong Farxiga performance, to $8,034m and represented 21% of overall Total Revenue (FY 2020: 27%). Glenmark Pharmaceuticals Inc has received United States Food & Drug Administration (FDA) approval for Dapagliflozin tablets, 5 mg and 10 mg, the generic version of Farxiga tablets, 5 mg and 10 mg, of AstraZeneca AB. According to IQVIATM sales data for the 12 month period ending January 2020, the Farxiga tablets, 5mg and 10 mg market achieved annual sales of approximately $1.8 billion. Also … After delivering revenue growth of 67% year-over-year, Farxiga reached $1 billion in quarterly sales for the first time during the first three months of 2022. Dapagliflozin, as Farxiga, currently has FDA labeling for multiple indications: to improve glycemic control in adults with type 2 diabetes; to reduce the risk for hospitalization for heart failure … Much of the attention on AstraZeneca PLC in the past couple of years has focused on its blooming oncology franchise but its top earner is the pipeline-in-a-product Farxiga and sales of the SGLT2 inhibitor, which is approved type 2 diabetes, heart failure and chronic kidney disease, have soared again in the second quarter. Speaking to Scrip as the UK-headquartered giant unveiled its latest set … Dapagliflozin drug usage statistics for the United States (2014 – 2024). Statistics include drug synonyms and therapeutic classes, including: Dapagliflozin 2,3-butanediol Monohydrate, Dapagliflozin Propanediol, Dapagliflozin, Farxiga, Sodium-Glucose Cotransporter 2 Inhibitor. The comprehensive new report detailing FARXIGA's impact and projected growth in the myocardial infarction treatment landscape over the next decade is now available, offering crucial insights into … Read on for Farxiga (dapagliflozin) dosage information, including typical dosage, adjustments for health conditions, and what to do if you miss a dose. Cardiovascular, Renal and Metabolism (CVRM) sales were up 16% in the quarter. Farxiga sales were up 21% to $1.9 billion. Brilinta sales were $341 million, up 4%. Crestor sales were up 5% to $261 million. Respiratory & Immunology (R&I) sales in the quarter were up 27% to $2.1 billion. Symbicort sales were $684 million, up 31%. Fasenra sales were up 12% to $471 million. Breztri sales were up 29% … Key Market Driver: Increasing diabetes prevalence drives market demand, with global diabetic population growing by nearly 51% between 2020 and 2030. Major Market Restraint: Patent expiration and generic competition expected to reduce branded sales share by about 28% across major markets. AstraZeneca's product, Farxiga (dapagliflozin), was first approved by the USFDA in 2014 [24]. Although AstraZeneca's Farxiga is protected by a patent until 2025 and the company successfully defended its patent against a generic challenge in 2021 [25], generic dapagliflozin is now available in the United States. In 2019, the US FDA approved Farxiga to reduce the risk of hospitalisation for heart failure in adult patients with T2D and established cardiovascular disease or multiple cardiovascular risk factors. AstraZeneca has started 2020 strongly, with the FDA granting a fast review for its big-selling Farxiga in heart failure and a key drug approval in China. DelveInsight's FARXIGA Market report covers size, trends, competitive landscape, and future outlook. Stay updated on the latest developments and forecasts. FARXIGA® (dapagliflozin), a medication for people with chronic kidney disease (CKD), heart failure, and type 2 diabetes. AstraZeneca has generated over $20.9 billion in sales revenue from Farxiga since its launch in 2014. Revenues obtained by AstraZeneca through Farxiga sales are nearly 30 times the median cost for research and development of a new drug estimated by experts. Prescription medicine sales data for Forxiga compiled from GlobalData's pharmaceutical product revenue figures on PMLiVE's Top Pharma List.